Compare Kisqali vs. Verzenio
Head-to-head comparisons of medication uses, side effects, warnings, and more.
- Kisqali (ribociclib)Verzenio (abemaciclib)
- Kisqali (ribociclib)Verzenio (abemaciclib)
Summary of Kisqali vs. Verzenio
Summary for Cyclin-dependent kinase (CDK) inhibitorPrescription onlyKisqali (ribociclib) is a medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It belongs to a drug class called CDK4/6 inhibitors, which help slow or stop cancer cells from growing. You typically take a tablet by mouth once a day for 21 days, then take 7 days off, repeating this 28-day cycle. It’s often taken together with other hormone treatments, like aromatase inhibitors or fulvestrant. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.
Summary for Cyclin-dependent kinase (CDK) inhibitorPrescription onlyVerzenio (abemaciclib) is an oral medication used to treat certain types of breast cancer. It's FDA approved for hormone receptor-positive, human epidermal growth factor 2-negative (HR+, HER2‑) breast cancer, including early and advanced or metastatic stages. This medication belongs to a group called CDK4/6 inhibitors, which slow down the growth of cancer cells. It comes as a pill that’s taken by mouth twice a day, without breaks. You might take Verzenio (abemaciclib) on its own or with hormone therapy. Common side effects include diarrhea, low white blood cell counts, and tiredness.
Indications of Kisqali vs. Verzenio
Indications for•Early breast cancer (HR+, HER2-), used with an aromatase inhibitor in adults at high risk of the cancer coming back•Advanced or metastatic breast cancer (HR+, HER2-), used with•An aromatase inhibitor as the first hormone-based treatment OR•Fulvestrant either as the first treatment or after the cancer has stopped responding to hormone-based treatmentIndications for•Early breast cancer (HR+, HER2-), used with tamoxifen or an aromatase inhibitor in adults at high risk of the cancer coming back•Advanced or metastatic breast cancer (HR+, HER2-), used with•An aromatase inhibitor as the first hormone-based treatment OR•Fulvestrant either as the first treatment or after the cancer has stopped responding to hormone-based treatment•Advanced or metastatic breast cancer (HR+, HER2-), used alone if the cancer has worsened after both hormone-based treatment and chemotherapyPros and Cons of Kisqali vs. Verzenio
Pros and Const for Cyclin-dependent kinase (CDK) inhibitorPros•Taken by mouth once a day•A first-choice treatment option for HR+, HER2- breast cancer•Can be taken with or without foodCons•Common side effects include nausea, tiredness, and headache•Requires regular blood tests to monitor for side effects•Interacts with many medicationsPros and Const for Cyclin-dependent kinase (CDK) inhibitorPros•Taken by mouth twice a day, every day without breaks•Can be taken with or without foodCons•Can cause severe diarrhea and low white blood cells•Requires regular blood tests to monitor for side effects•Interacts with many products and medicationsCommon Side Effects of Kisqali vs. Verzenio
Common Side Effects forEarly breast cancer
•Lower white blood cell counts (up to 97%)•Lower red blood cell counts (47%)•Higher liver enzymes (up to 45%)•Infections (37%)•Higher creatinine levels (33%)•Lower platelets (28%)•Headache (23%)•Nausea (23%)•Tiredness (22%)Advanced or metastatic breast cancer
•Lower white blood cell counts (up to 95%)•Lower red blood cell counts (68%)•Higher liver enzymes (up to 55%)•Nausea (47%)•Infections (47%)•Higher creatinine levels (42%)•Tiredness (35%)•Low red blood cell count•Lower appetite•Dizziness•Trouble sleeping•Trouble breathing•Swollen or sore mouth•Stomach pain•Fever•Pain or swelling in arms or legs•Liver problems•Lower platelets (34%)•Diarrhea (33%)•Vomiting (29%)•Headache (27%)•Constipation (25%)•Hair loss (25%)•Cough (24%)•Rash (24%)•Back pain (24%)•Lower blood sugar (20%)Note: Side effects listed above were reported in studies where people took Kisqali (ribociclib) with another hormone medication.
Common Side Effects for•Rise in creatinine (99%)•Lower white blood cell count (up to 91%)•Diarrhea (90%)•Anemia (69%)•Tiredness (65%)•Nausea (64%)•Reduced appetite (45%)•Lower platelet count (41%)•Stomach pain (39%)•Vomiting (35%)•Infections (31%)•Rise in liver enzymes (up to 31%)•Headache (20%)Note: Side effects listed above are from a study of Verzenio (abemaciclib) used alone to treat metastatic breast cancer.
Warnings of Kisqali vs. Verzenio
Common Side Effects for•Lung problems•Severe skin reactions•Heart rhythm problem (QT prolongation)•Liver problems•Low white blood cell counts•Harm to unborn babyCommon Side Effects for•Diarrhea•Low white blood cell counts•Lung problems•Liver problems•Blood clots•Harm to unborn babyPrices with our coupons for Kisqali vs. Verzenio
Compare other Breast Cancer drugs
Browse medications
View AllResearch prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.